Dianhydrogalactitol induces replication-dependent DNA damage in tumor cells preferentially resolved by homologous...

Area of Science:

• Molecular oncology
• DNA repair mechanisms
• Cancer cell biology

Background:

• 1,2:5,6-Dianhydrogalactitol (DAG) is a DNA-targeting agent used in glioblastoma clinical trials.
• DAG causes N7-guanine alkylation and inter-strand DNA crosslinks, demonstrating antitumor activity.
• Understanding DAG's molecular cytotoxicity mechanisms is crucial for clinical application.

Purpose of the Study:

• To elucidate the molecular mechanisms of DAG-induced cytotoxicity in non-small cell lung cancer (NSCLC).
• To investigate the role of DNA damage and repair pathways in DAG's anti-cancer effects.

Main Methods:

• Utilized NSCLC as a model system to study DAG's effects.
• Analyzed DNA crosslink repair and cell cycle progression post-DAG treatment.
• Investigated the impact of homologous recombination (HR) pathway inhibition on DAG sensitivity.

Main Results:

• DAG-induced cytotoxicity occurs when cells with unrepaired N7-guanine DNA crosslinks enter S phase.
• DAG lesions transform into replication-dependent DNA double-strand breaks (DSBs) in S phase.
• DSBs lead to irreversible cell cycle arrest and loss of viability.
• DAG-treated NSCLC cells attempt DSB repair via homologous recombination (HR).
• Inhibiting the HR pathway sensitizes NSCLC cells to DAG-induced DNA damage.

Conclusions:

• A molecular mechanism for N7-guanine crosslink-induced cytotoxicity in cancer cells is described.
• DAG's efficacy is linked to DSB formation and cell cycle arrest during S phase.
• DAG analogs may be effective treatments for HR-deficient tumors.